Business Wire

IN-NTT/NTT-DATA

23.5.2024 16:06:30 CEST | Business Wire | Press release

Share
NTT and NTT DATA Roar into the Indianapolis 500 with AI-powered Fan Experience

NTT, a leading global technology and business solutions provider, and NTT DATA continue to expand innovative use of racing data to improve fan experiences across the NTT INDYCAR SERIES, including this year’s Indianapolis 500.

NTT is the parent company of NTT DATA, and they serve together as Official Technology Partner of INDYCAR, the NTT INDYCAR SERIES, Indianapolis Motor Speedway (IMS), the Indianapolis 500, and NASCAR Brickyard weekend.

Through 140-plus sensors on each racecar, NTT DATA captures and analyzes more than 8 billion racing datapoints in the NTT Smart Solutions Platform. Leveraging advanced AI and predictive analytics, the company shares near-real-time insights and visualizations to fans both onsite and remotely for enhanced storytelling of key moments during events including head-to-head overtaking, race strategies, race winner predictions and more. Additionally, the 300,000-plus fans onsite for the race benefit from data on wait times and flow across the 600-plus acre venue calibrated every 30 seconds.

SMART Venues Improve the Fan Experience
Fans at the Indianapolis 500 or other events at the Indianapolis Motor Speedway can experience NTT DATA Smart Venue technology, sustainability solutions and live race data at the Pagoda command displays. For example, AI-enabled optical detection technologies improve security and traffic flow, and when combined with digital ticketing, provide real-time and future prediction wait times at the event gates and concessions. This allows fans at the world’s largest single-day sporting event to move through the venue as safely and efficiently as possible.

AI-enabled Racing Insights
Whether at the racetrack, at home or on the go, fans of the NTT INDYCAR SERIES can also tap into the INDYCAR App Powered by NTT DATA to stay up to date on all of the latest developments. The App allows fans to get even closer to the action with real-time, AI and advanced analytics providing racing insights that include live scoring and viewing of the drivers in action courtesy of 15 in-car cameras. The App, which historically engages more than 70,000 users on race days, is available for download from the iOS App Store and Google Play.
NTT DATA also continues to enable other similar innovative experiences to benefit fans and increase engagement across all mediums, via social media, the web and television or streaming broadcast, through reliable technology and services that deliver deeper data insights.

Race Like the Pros
This year, a new limited racing demonstration will leverage Embodied Knowledge technology from NTT R&D. Embodied Knowledge powers simulators that blend physical sensations with digital innovation, allowing users to precisely experience a track as driven by a professional driver. Beyond the experience of traditional simulators, Embodied Knowledge adds the actual feel and performance of the professional driver at high speeds at the Indianapolis Motor Speedway including realistic steering wheel forces and car behavior like vibrations and forces exerted on seat, users can synchronize their movements with that of a professional driver via XR.

NTT Embodied Knowledge technology is being explored for future use cases including medical surgery training, coaching and fan experiences in sports. Future applications include employee training across retail, education, and manufacturing, as well as enabling AI-robots to learn how to move and react the way humans do to perform tasks from restocking shelves to in-home caregiving. The effort is part of the more than $3.6B NTT invests each year in research and development, uncovering innovations that have commercial impact for their customers.

“The Indianapolis 500 is the pinnacle of racing that leverages refined Embodied Knowledge where firsthand the movements of racers can be felt to understand what Embodied Knowledge truly means. Through various sensing technologies, we aim to technically recreate these movements and sensations.” said Kota Hidaka, Vice President, Head of NTT Human Informatics Laboratories.

To learn more about the NTT INDYCAR SERIES, visit: https://us.nttdata.com/en/about-us/content/ntt-indycar-series.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240523988191/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye